| DOTATOC PET/CT for Imaging NET Patients (NCT03583528) | British Columbia Cancer Agency | 2018-07-11 |
| Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors (NCT02259725) | University of Southern California | 2016-08-16 |
| Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer (NCT02273752) | Emory University | 2014-11-01 |
| Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors (NCT02108782) | Academic and Community Cancer Research United | 2014-10-01 |
| Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery (NCT02031536) | ECOG-ACRIN Cancer Research Group | 2014-04-10 |
| Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors (NCT01824875) | ECOG-ACRIN Cancer Research Group | 2013-08-08 |
| Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors (NCT01525082) | Shaheen Shagufta | 2012-12-01 |
| Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors (NCT00131911) | National Cancer Institute (NCI) | 2005-06-01 |
| Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (NCT00655655) | Mayo Clinic | 2004-12-01 |
| Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors (NCT00084461) | National Cancer Institute (NCI) | 2004-03-01 |
| Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors (NCT00075439) | National Cancer Institute (NCI) | 2003-12-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |
| Evaluating Patients With Abnormal Levels of Gastric Acid (NCT00001240) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1989-01-01 |